BLACK FRIDAY SALE: 20% OFF SITEWIDE PRODUCTS – USE CODE [BF2024] AT CHECKOUT
(£)
GBP (Default)
- ($) USD
- (€) EUR
- ($) AUD
- ($) CAD
- ($) NZD
£99.00 – £267.30
ACE-031 is a soluble version of the activin receptor type IIB (ActRIIB), which acts as a powerful regulator of muscle growth by binding to myostatin and other muscle mass regulators. It has been investigated for potential therapeutic applications, particularly in the treatment of muscle illnesses like Duchenne muscular dystrophy (DMD). The peptide has been shown to increase bone density while also preserving muscle function, providing interesting pathways for future study and development in muscle-related disorders.
Pre Mixed Cartridge and Kit:
Single Mixed Cartridges (1,2 & 3) Come with:
The single 1,2 & 3 cartridges do not come with a kit. Save 10% when buying 3 cartridges.
495 in stock
This product is intended for research purposes only. To be used by trained professionals only.
ACE-031 Peptide is a therapeutic protein that has generated substantial interest in the field of medical research due to its potential applications in muscle-related illnesses. This peptide belongs to the protein family and functions as a soluble version of the activin receptor type IIB (ActRIIB). ActRIIB is well-known for its critical role in muscle development regulation, which ACE-031 pre mixed peptide takes use of in its mechanism of action.
The operation of ACE-031 is remarkable. It binds to myostatin and other related ligands that impede muscle and protein development, thereby neutralising the inhibitory effects of these ligands. Myostatin, in particular, is a protein generated by skeletal muscle cells that regulates muscular growth. By blocking the effects of myostatin, ACE-031 pre mixed peptide promotes a favourable environment for muscle development and preservation [1].
ACE-031 therapy was usually well tolerated in Finland clinical trials and resulted with increases in muscle mass in healthy postmenopausal women. Furthermore, it has been widely researched for its possible therapeutic effects in the treatment of Duchenne muscular dystrophy (DMD), a severe kind of muscular dystrophy [2]. Preliminary studies suggest that this peptide may boost bone density and preserve muscular function in DMD patients, opening the door to future DMD therapeutics.
While ACE-031 is now utilised exclusively in Finland laboratory research, its prospective applications extend far beyond this. Some research suggests that ACE-031 pre mixed peptide may also improve bone metabolism and decrease fat buildup, broadening its potential therapeutic use. More research, however, is required to fully grasp the peptide’s potential and safety profile.
In conclusion, ACE-031 is a powerful muscle regulator with therapeutic potential. Its potential to block muscle growth inhibition and increase bone metabolism makes it an intriguing prospect for future research and development in the treatment of muscle-related diseases [3].
[1] https://pubmed.ncbi.nlm.nih.gov/ 23169607/
[2] https://pubmed.ncbi.nlm.nih.gov/ 27462804/
[3] https://www.clinicaltrialsarena.com /projects/ace031forthetreatmen/
ALL CONTENT AND PRODUCT INFORMATION AVAILABLE ON THIS WEBSITE IS FOR EDUCATIONAL PURPOSES ONLY.
DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our Finland Direct Peptides website: https://finland.direct-peptides.com is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.
BUY ACE-031 Pre Mixed Peptide Pen ONLINE today From Finland Direct Peptides
401 N. Mills Ave, Ste B, Orlando, FL 32803, United States
